| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bullfrog AI Holdings, Inc. Common Stock$0.66
0 (+0.35%)
Market Cap
16.34 M
EPS
-0.64
P/E Ratio
-1.39 $
Value Trade
179.63 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
1.99 M
Monthly Burn
12.35 K
Runway
12,345 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
154.54 K
52 Week Range
0.43 - 2.12
% held by Insiders
12.87 %
% held by Institutions
2.87 %
Enterprise Value
14.15 M
Total Shares
18.53 M
Short %
3.55 %
Float Shares
15.81 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BFRG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Bullfrog AI Holdings, Inc. Common Stock (BFRG) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BFRG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BFRG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BFRG
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BFRG Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BFRG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BFRG
Apr 22, 2026BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement Strengthened balance sheet provides capital runway into late 2027 GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, as confirmed by a notification received on April 21, 2026. This compliance was achieved through recent sales under their existing financial facilities. The company has also secured a commercial agreement with a major pharmaceutical player, enhancing its credibility in the market. However, they will be monitored for one year, and failure to maintain compliance could lead to severe consequences, including delisting.
Read more →-BFRG
Apr 13, 2026BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners First commercial agreement w
BullFrog AI Holdings, Inc. announced a business update highlighting its strengthened balance sheet and execution capabilities. The company closed its first commercial feasibility agreement with a top 5 global pharmaceutical company, focusing on drug targets for major depressive disorder. This agreement underscores the company's active role in transforming pharmaceutical R&D through its AI technology, validated by a significant upfront milestone payment structure. BullFrog aims to expand its commercial activities with additional partnerships and collaborations in the biotech space.
Read more →-BFRG
Mar 30, 2026BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder Commercial agreement serves as high-profile third party valid
BullFrog AI has entered into a commercial agreement with a leading global pharmaceutical company to utilize its bfLEAP platform for identifying therapeutic targets in major depressive disorder (MDD). This partnership serves as a strong validation of BullFrog AI's AI-driven capabilities in drug discovery and development. The MDD market, which was valued at over $8 billion in 2025, is expected to experience substantial growth, indicating promising prospects for the collaboration. The CEO expressed confidence that this relationship may expand to other research areas within the customer's portfolio.
Read more →-BFRG
Dec 30, 2025BullFrog AI Publishes Annual Letter to Shareholders Highlights significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026 GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. has released its annual letter to shareholders, highlighting significant advancements made in 2025 and outlining strategic priorities for 2026. The company has engaged in key collaborations with notable pharmaceutical organizations and evidenced successful deployment of its technology within clinical development, particularly in oncology. BullFrog AI's ongoing discussions and commercial partnerships suggest a promising path for growth and transformative opportunities in the upcoming year. Furthermore, the introduction of their AI-powered data preparation tool, bfPREP, marks a significant innovation aimed at optimizing the drug development process.
Read more →-BFRG
Jun 12, 2025BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients GAITHERSBURG, Md.
BullFrog AI has announced a strategic collaboration with Sygnature Discovery, which will facilitate the introduction of BullFrog Data Networks to Sygnature's global biopharma clients. This partnership is expected to significantly boost BullFrog AI's brand recognition and projected revenues, potentially generating between $15-$30 million through 2028. BullFrog Data Networks utilizes AI to enhance drug discovery processes, enabling researchers to analyze complex biological data efficiently. However, there are risks associated with reliance on Sygnature's marketing efficacy and market competition.
Read more →-BFRG
Feb 27, 2025BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial Eleison to leverage BullFrog Data Networks TM to enhance patient clustering and safety analysis in glufosfamide cli
BullFrog AI and Eleison Pharmaceuticals have announced a collaboration agreement to optimize Eleison's Phase 3 clinical trials of glufosfamide, a treatment for pancreatic cancer. BullFrog AI will leverage its Data Networks and bfLEAP AI technology to improve trial efficiency and patient insights. The partnership aims to enhance patient clustering and safety analysis, potentially accelerating the market entry of the therapies in Eleison's oncology pipeline. The trial for glufosfamide is anticipated to be completed by 2027.
Read more →-BFRG
Dec 27, 2024BullFrog AI Issues Letter to Stockholders GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. issued a letter to stockholders highlighting its significant progress in AI-driven drug development throughout 2024. The company has advanced its proprietary bfLEAP platform and established collaborations, particularly with the Lieber Institute for Brain Development, yielding insights into neuropsychiatric disorders. Additionally, BullFrog announced the expansion of research on its promising drug candidate BF-114 and strengthened its intellectual property portfolio with new patent protections. With a robust cash position and the addition of key experts to its team, the outlook for 2025 is optimistic.
Read more →-BFRG
Dec 17, 2024BullFrog AI Announces Appointment of Chief Financial Officer GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. has announced the appointment of Josh Blacher as its Chief Financial Officer following the death of former CFO Dane Saglio. Blacher brings over two decades of financial experience within the life science sector, indicating strong potential for advancing the company's financial strategy. His role is pivotal as BullFrog AI aims to leverage artificial intelligence in drug development amidst a transition period characterized by the loss of a key leader.
Read more →-BFRG
Oct 18, 2024Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million GAITHERSBURG, Md.
Bullfrog AI Holdings, Inc. has announced a registered direct offering and concurrent private placement expected to yield aggregate gross proceeds of $3.13 million. The deal involves the sale of 1,565,000 shares of common stock at a purchase price of $2.00 each, accompanied by warrants to buy an equal number of shares. The closing of this offering is slated for approximately October 21, 2024, pending customary closing conditions. The capital raised is part of Bullfrog's strategy to further advance its technology-enabled drug development initiatives.
Read more →-BFRG
Oct 15, 2024BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni GAITHERSBURG, Md.
BullFrog AI has appointed Dr. John Baldoni, a seasoned veteran from GSK, to its Scientific Advisory Board. Dr. Baldoni brings over 40 years of pharmaceutical experience, particularly in drug discovery and development. His leadership and insights are anticipated to enhance the company's innovative efforts, specifically in the commercialization of the bfLEAP platform, which utilizes AI for drug development. Dr. Baldoni expressed enthusiasm about collaborating with BullFrog AI to leverage AI technologies in improving drug discovery.
Read more →-BFRG
Oct 9, 2024BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114 - The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of
BullFrog AI has published new research in Cell Reports regarding its liver disease treatment candidate, BF-114. The study, led by Dr. Lopa Mishra, suggests that BF-114 may effectively target 2-spectrin to prevent the progression of liver diseases such as MASLD, MASH, and HCC. This research reinforces previous findings and highlights the potential of BF-114 to address unmet medical needs in treating obesity-related liver conditions. Dr. Mishra's expertise will support the continued development of BF-114 as BullFrog AI aims to explore various therapeutic applications.
Read more →-BFRG
Jul 25, 2024BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets Discussions underway for drug target discovery deals with potential pharma partners GAI
BullFrog AI Holdings, Inc. announced advancements in its collaboration with the Lieber Institute for Brain Development, focusing on bipolar disorder. New analysis has identified specific molecular pathways and gene clusters linked to the condition, which could enable the development of targeted therapeutics. The findings indicate significant involvement of various brain regions, leading to hopes for more effective treatments. The company plans to validate these discoveries further and collaborate with pharmaceutical partners to enhance drug target discovery.
Read more →-BFRG
May 16, 2024BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders Gaithersburg, MD
BullFrog AI Holdings, Inc. has announced a significant advancement in its collaboration with the Lieber Institute for Brain Development, focused on identifying novel drug targets for neuropsychiatric disorders such as major depression, schizophrenia, and bipolar disorder. Utilizing advanced AI techniques, the collaboration has successfully identified biological subgroups that could lead to targeted therapeutics. Furthermore, the partnership exemplifies the integration of AI with extensive brain data to enhance the understanding and treatment of complex brain conditions. Both organizations are optimistic about the prospects of these findings in developing effective treatments for patients.
Read more →-BFRG
Apr 9, 2024BullFrog AI's CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo Gaithersburg, MD
BullFrog AI Holdings, Inc. announced that its Chief Scientific Officer, Tom Chittenden, will present at the Quantum Computing Symposium during the upcoming Bio-IT World Conference & Expo in Boston. His presentation titled 'Quantum Assisted AI/ML for Precision Medicine' will discuss how quantum computing can enhance understanding of complex diseases. The symposium emphasizes the significant role of quantum technology in transforming pharmaceuticals and aims to highlight innovative strategies in drug development research.
Read more →-BFRG
Mar 7, 2024BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute Gaithersburg, MD
BullFrog AI has announced the availability of a recording of a recent fireside chat featuring its CEO, Vin Singh, and Dr. Daniel R. Weinberger from the Lieber Institute. The discussion highlighted groundbreaking findings from their collaboration, exploring psychiatric disorders through the use of advanced graph analytics and over 2,800 brain samples. This innovative approach has allowed for the identification of biological subtypes within various psychiatric conditions, potentially leading to more effective treatments. Additionally, the findings may create opportunities for future partnerships with pharmaceutical firms.
Read more →-BFRG
Feb 26, 2024BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer Gaithersburg, MD
BullFrog AI Holdings has appointed Dr. Thomas W. Chittenden as its new Chief Scientific Officer, effective February 26, 2024. Dr. Chittenden has a prestigious background in artificial intelligence, machine learning, and drug discovery, previously holding key roles at BioAI Health and HiberCell. His expertise is anticipated to drive advancements in BullFrog AI's scientific strategy and bolster its proprietary bfLEAP platform. The company aims to revolutionize drug development through innovative AI technologies.
Read more →-BFRG
Feb 9, 2024BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip Gaithersburg, MD
BullFrog AI Holdings, Inc. will participate in a fireside chat with the Lieber Institute for Brain Development on March 5, 2024. The discussion will focus on their collaborative research, which has successfully stratified brain expression data to better understand psychiatric conditions such as schizophrenia and bipolar disorder. This groundbreaking partnership has utilized over 2,800 brain samples, leading to the identification of potential biological subtypes within disorders, which could enhance targeted treatment development.
Read more →-BFRG
Jan 26, 2024BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala Gaithersburg, MD
BullFrog AI Holdings, Inc. has strengthened its Scientific Advisory Board with the addition of Dr. Gwenn Smith and Dr. Jeremiah Wala. Dr. Smith, from Johns Hopkins University, specializes in neuropsychiatry, while Dr. Wala, from Dana-Farber Cancer Institute, focuses on cancer genomics. Their expertise is expected to enhance BullFrog AI's mission of developing innovative therapies using AI and machine learning. The company's proprietary bfLEAP platform aims to streamline drug development processes and improve patient outcomes.
Read more →-BFRG
Jan 17, 2024BullFrog AI's Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data Gaithersburg, MD
BullFrog AI Holdings has announced early results from its collaboration with the Lieber Institute for Brain Development, which may change the landscape of psychiatric disorder treatment. Utilizing AI and machine learning, they have stratified brain expression data, uncovering biological insights relevant to disorders such as schizophrenia and bipolar disorder. These findings indicate potential pathways for developing more targeted therapies, enhancing personal treatment strategies. This partnership is positioned to leverage LIBD's extensive brain data, creating opportunities for commercialization of new treatment methods.
Read more →-BFRG
Jan 16, 2024BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer Issued patent provides protection for BF-223 and related compounds Gaithersburg, MD - Date - B
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced the issuance of an Australian patent protecting its novel prodrugs derived from mebendazole, specifically BF-223, which has demonstrated anticancer activity for glioblastoma in preclinical studies. This patent follows a similar issuance in the United States and enhances the company’s intellectual property portfolio. The prodrugs are designed to improve solubility and oral bioavailability, addressing challenges associated with mebendazole in oncology treatments. The company plans to collaborate with strategic partners to monetize this promising asset.
Read more →-BFRG
Dec 29, 2023BullFrog AI Issues Letter to Shareholders GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. issued a letter to shareholders detailing its achievements and future objectives. The company highlighted a successful IPO, partnerships with prominent research institutions, and advancements in its drug development programs. BullFrog AI plans to focus on commercial operations and revenue generation while maintaining a lean operational structure. The CEO expressed optimism about the company's prospects in 2024, emphasizing its commitment to revolutionizing drug development using AI technology.
Read more →-BFRG
Oct 5, 2023BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP Platform Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP platform
BullFrog AI Holdings, Inc. announced the identification of new potential drug targets for colorectal cancer through its AI-driven bfLEAP platform. The company discovered three novel targets and 14 candidates significantly over-expressed in tumors. These findings will be validated in partnership with the J. Craig Venter Institute, leveraging their expertise in genomics. This approach presents a streamlined way to identify actionable drug targets in a field that has been studied for years, showcasing the innovative capabilities of BullFrog's technology.
Read more →-BFRG
Sep 26, 2023Healthcare Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblasto
BullFrog AI Holdings, Inc. announced positive results from a preclinical study of its novel prodrug BF-223, which demonstrated anti-cancer activity against glioblastoma in animal models. The study showed BF-223 provided a survival benefit and significant tumor growth reduction compared to placebo. These promising results highlight BF-223's improved properties over previous formulations and may enhance its development potential. The company is pursuing partnerships for further advancement of BF-222 and BF-223 amid a growing glioblastoma treatment market.
Read more →-BFRG
Sep 20, 2023Healthcare Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment BullFrog AI Announces Launch of BullFrog Data Networks , a Data Insights Tool Powered by the bfLEAP Platform Purpose-built Dat
BullFrog AI Holdings, Inc. has announced the launch of BullFrog Data Networks, a data insights tool powered by the bfLEAP platform. This platform allows for comprehensive evaluation of high-dimension, multi-modal data, generating visual representations of complex relationships within specific disease indications. It aims to facilitate drug development by offering customizable data analysis solutions designed to uncover novel insights and optimize clinical trials. Touted as enhancing the drug development process, it is positioned as a critical component of BullFrog AI's growth strategy.
Read more →-BFRG
Sep 13, 2023Healthcare Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment BullFrog AI Announces Three - Year Global Strategic Partnership with the Lieber Institute for Brain Development The Strategic
BullFrog AI Holdings, Inc. has announced a three-year strategic partnership with the Lieber Institute for Brain Development to leverage its bfLEAP AI platform. The collaboration aims to explore relationships between genetics and brain disorders, focusing on the development of new therapeutics for psychiatric and neurologic diseases. The partnership includes a one-year exclusivity for data analysis, with options for extension based on performance milestones. This agreement represents a significant step forward in using AI to enhance precision medicine.
Read more →-BFRG
Jul 25, 2023BullFrog AI Announces Issuance of U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer Novel compounds show improved bioavailability relative to mebendazole Gaithersburg, MD
BullFrog AI Holdings, Inc. has announced the issuance of U.S. Patent No. 11,712,435, which protects their novel prodrugs derived from mebendazole for cancer treatment. The new compounds show improved solubility and oral bioavailability compared to mebendazole, marking a significant advancement in oncology therapies. This patent, the first stemming from a license with Johns Hopkins University, strengthens BullFrog AI's product portfolio and enhances the likelihood of clinical success. The company aims to monetize these promising assets in collaboration with strategic partners.
Read more →-BFRG
Jul 11, 2023BullFrog AI Announces Appointment of Enrique Garc a-Rivera as Vice President of Artificial Intelligence New VP will enhance development of industry-leading bfLEAP AI platform to accelerate and optimize drug discovery pro
BullFrog AI Holdings, Inc. has appointed Dr. Enrique Garc a-Rivera as Vice President of Artificial Intelligence to enhance its bfLEAP AI platform. This new role is aimed at improving drug discovery processes and optimizing clinical trial designs, leveraging Dr. Garc a-Rivera's extensive experience in AI and biomedical research. His previous positions at ROME Therapeutics and nference, along with his academic credentials, are expected to strengthen BullFrog AI's capabilities in precision medicine. The company continues to pursue advancements in AI-driven drug development, collaborating with leading research institutions.
Read more →-BFRG
Jun 9, 2023BullFrog AI CEO Vin Singh to Present at the Gujarati Physicians Convention 2023 More than 1,000 physicians expected to attend the Continuing Medical Education program, where this year's scientific program theme is "Futur
BullFrog AI Holdings, Inc. (NASDAQ:BFRG) announced that CEO Vin Singh will present at the Gujarati Physicians Convention in Atlantic City on June 10, 2023. The convention, expecting over 1,000 physicians, focuses on the theme of 'Futuristic Medicine' and aims to facilitate networking and education around new medical advances. BullFrog AI, a leader in precision medicine utilizing AI and machine learning, is set to deliver insights on its proprietary platform, bfLEAP, aimed at improving drug development efficiency.
Read more →-BFRG
Jun 5, 2023BullFrog AI Strengthens Capabilities of its AI Platform through Expansion of Licensing Agreement with Johns Hopkins Applied Physics Laboratory Gaithersburg, MD
BullFrog AI Holdings, Inc. has announced an expansion of its global license agreement with the Johns Hopkins Applied Physics Laboratory, enhancing its AI platform, bfLEAP. This strengthened partnership aims to improve drug development efficiency and patient outcomes by utilizing advanced analytical models. The updated capabilities of bfLEAP include new algorithms for analyzing diverse datasets, aiming to decrease overall development costs and streamline the therapeutic development process. This initiative positions BullFrog AI as a leader in AI-driven drug development, contributing to the broader goal of precision medicine.
Read more →-BFRG
May 26, 2023BullFrog AI Files Quarterly Report on Form 10-Q Gaithersburg, MD
BullFrog AI Holdings, Inc. filed its Quarterly Report on Form 10-Q with the SEC for the quarter ended March 31, 2023, and has resolved prior non-compliance issues with Nasdaq regulations. The company is focusing on leveraging its proprietary bfLEAP AI platform to enhance precision medicine by predicting patient responses to therapies. Despite achieving compliance, the company faces uncertainties regarding future performance and competition in the evolving digital health landscape.
Read more →-BFRG
Apr 25, 2023BullFrog AI Files 2022 Annual Report on Form 10-K Gaithersburg, MD
BullFrog AI Holdings, Inc. has filed its 2022 Annual Report on Form 10-K, addressing prior compliance issues with Nasdaq. The CEO noted that this filing largely mirrored their S-1 IPO filing, which caused the delays. The completion of the filing is expected to prevent future delays in submissions. The company is recognized for its application of machine learning in precision medicine, particularly through its proprietary bfLEAP AI platform.
Read more →Competitive Position
How BFRG ranks across every disease it competes inCompetitive Position is a premium feature
See how BFRG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial